GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immutep Ltd (ASX:IMM) » Definitions » Accounts Receivable

Immutep (ASX:IMM) Accounts Receivable : A$0.16 Mil (As of Dec. 2023)


View and export this data going back to 1988. Start your Free Trial

What is Immutep Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Immutep's accounts receivables for the quarter that ended in Dec. 2023 was A$0.16 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Immutep's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was A$0.08.


Immutep Accounts Receivable Historical Data

The historical data trend for Immutep's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immutep Accounts Receivable Chart

Immutep Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Accounts Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.93 - 0.05 0.02 0.13

Immutep Quarterly Data
Jun18 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Accounts Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.13 - 0.16 -

Immutep Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.


Immutep Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Immutep's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0.161/0*91
=

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Immutep's accounts receivable are only considered to be worth 75% of book value:

Immutep's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(103.735+0.75 * 0.161+0.5 * 0-8.146
-0-0)/1188.83
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.


Immutep Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Immutep's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Immutep (ASX:IMM) Business Description

Traded in Other Exchanges
Address
264 George Street, Level 33, Australia Square, Sydney, NSW, AUS, 2000
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trails, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia and derives the majority of the revenue from the sale of the products.

Immutep (ASX:IMM) Headlines

No Headlines